Literature DB >> 1702301

HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide.

P J Durda1, L Bacheler, P Clapham, A M Jenoski, B Leece, T J Matthews, A McKnight, R Pomerantz, M Rayner, K J Weinhold.   

Abstract

We have developed a series of murine monoclonal antibodies to a region of the 120 kD envelope glycoprotein (gp120) of human immunodeficiency virus type 1 (HIV-1). This region has previously been implicated as a site for virus neutralization by antisera raised to recombinant proteins and by antibodies made to full-length gp120 purified from virus. The antigen employed was a synthetic peptide containing 15 amino acids, representing amino acid residues 308-322, RIQRGPGRAFVTIGK, of env gp120 (HTLV-IIIB isolate). Five of the monoclonal antibodies raised to this antigen have reactivity with gp120 from divergent strains of HIV-1 in Western blot assays. The two of these five which were tested with live cells infected with the divergent HIV-1 isolates IIIB, MN, and RF were specifically reactive by fluorescence analyses with cells infected with the MN and IIIB isolates. Four of the five monoclonal antibodies blocked the fusion of IIIB-infected cells with uninfected MOLT-4 target cells. The monoclonal antibody most reactive with MN-infected cells by fluorescence, #5025A, blocked the fusion of MN-infected cells with uninfected MOLT-4 cells. Four of the five monoclonal antibodies neutralized the IIIB isolate of HIV-1 in vitro, but none neutralized the MN or RF isolates at the levels of antibody tested (less than or equal to 50 micrograms/ml). Taken together these data indicate that monoclonal antibodies to the immunodominant neutralizing domain of HIV-1 gp120 display different levels of group reactivity depending on the assay system being examined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702301     DOI: 10.1089/aid.1990.6.1115

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

3.  Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.

Authors:  J D Laman; M M Schellekens; Y H Abacioglu; G K Lewis; M Tersmette; R A Fouchier; J P Langedijk; E Claassen; W J Boersma
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

4.  Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

Authors:  T C VanCott; J R Mascola; R W Kaminski; V Kalyanaraman; P L Hallberg; P R Burnett; J T Ulrich; D J Rechtman; D L Birx
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages.

Authors:  M A Handley; R T Steigbigel; S A Morrison
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  Human immunodeficiency virus type 1-like DNA sequences and immunoreactive viral particles with unique association with breast cancer.

Authors:  E M Rakowicz-Szulczynska; B Jackson; A M Szulczynska; M Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

7.  Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.

Authors:  J P Langedijk; N K Back; E Kinney-Thomas; C Bruck; M Francotte; J Goudsmit; R H Meloen
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.

Authors:  R Wagner; S Modrow; T Böltz; H Fliessbach; M Niedrig; A von Brunn; H Wolf
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.